Dataset Information

Robust phenotype prediction from gene expression data using differential shrinkage of co-regulated genes.

ABSTRACT: Discovery of robust diagnostic or prognostic biomarkers is a key to optimizing therapeutic benefit for select patient cohorts - an idea commonly referred to as precision medicine. Most discovery studies to derive such markers from high-dimensional transcriptomics datasets are weakly powered with sample sizes in the tens of patients. Therefore, highly regularized statistical approaches are essential to making generalizable predictions. At the same time, prior knowledge-driven approaches have been successfully applied to the manual interpretation of high-dimensional transcriptomics datasets. In this work, we assess the impact of combining two orthogonal approaches for the discovery of biomarker signatures, namely (1) well-known lasso-based regression approaches and its more recent derivative, the group lasso, and (2) the discovery of significant upstream regulators in literature-derived biological networks. Our method integrates both approaches in a weighted group-lasso model and differentially weights gene sets based on inferred active regulatory mechanism. Using nested cross-validation as well as independent clinical datasets, we demonstrate that our approach leads to increased accuracy and generalizable results. We implement our approach in a computationally efficient, user-friendly R package called creNET. The package can be downloaded at https://github.com/kouroshz/creNethttps://github.com/kouroshz/creNet and is accompanied by a parsed version of the STRING DB data base.

SUBMITTER: Zarringhalam K

PROVIDER: S-EPMC5775343 | biostudies-other | 2018 Jan

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Robust phenotype prediction from gene expression data using differential shrinkage of co-regulated genes.

Zarringhalam Kourosh K Degras David D Brockel Christoph C Ziemek Daniel D

Scientific reports 20180119 1

Discovery of robust diagnostic or prognostic biomarkers is a key to optimizing therapeutic benefit for select patient cohorts - an idea commonly referred to as precision medicine. Most discovery studies to derive such markers from high-dimensional transcriptomics datasets are weakly powered with sample sizes in the tens of patients. Therefore, highly regularized statistical approaches are essential to making generalizable predictions. At the same time, prior knowledge-driven approaches have been ...[more]

PMID: 29352257

Similar Datasets

Project description:BACKGROUND: Due to the growing amount of biological knowledge that is incorporated into metabolic network models, their analysis has become more and more challenging. Here, we examine the capabilities of the recently introduced chemical organization theory (OT) to ease this task. Considering only network stoichiometry, the theory allows the prediction of all potentially persistent species sets and therewith rigorously relates the structure of a network to its potential dynamics. By this, the phenotypes implied by a metabolic network can be predicted without the need for explicit knowledge of the detailed reaction kinetics. RESULTS: We propose an approach to deal with regulation - and especially inhibitory interactions - in chemical organization theory. One advantage of this approach is that the metabolic network and its regulation are represented in an integrated way as one reaction network. To demonstrate the feasibility of this approach we examine a model by Covert and Palsson (J Biol Chem, 277(31), 2002) of the central metabolism of E. coli that incorporates the regulation of all involved genes. Our method correctly predicts the known growth phenotypes on 16 different substrates. Without specific assumptions, organization theory correctly predicts the lethality of knockout experiments in 101 out of 116 cases. Taking into account the same model specific assumptions as in the regulatory flux balance analysis (rFBA) by Covert and Palsson, the same performance is achieved (106 correctly predicted cases). Two model specific assumptions had to be considered: first, we have to assume that secreted molecules do not influence the regulatory system, and second, that metabolites with increasing concentrations indicate a lethal state. CONCLUSION: The introduced approach to model a metabolic network and its regulation in an integrated way as one reaction network makes organization analysis a universal technique to study the potential behavior of biological network models. Applying multiple methods like OT and rFBA is shown to be valuable to uncover critical assumptions and helps to improve model coherence.

Project description:BackgroundStratification of patient subpopulations that respond favorably to treatment or experience and adverse reaction is an essential step toward development of new personalized therapies and diagnostics. It is currently feasible to generate omic-scale biological measurements for all patients in a study, providing an opportunity for machine learning models to identify molecular markers for disease diagnosis and progression. However, the high variability of genetic background in human populations hampers the reproducibility of omic-scale markers. In this paper, we develop a biological network-based regularized artificial neural network model for prediction of phenotype from transcriptomic measurements in clinical trials. To improve model sparsity and the overall reproducibility of the model, we incorporate regularization for simultaneous shrinkage of gene sets based on active upstream regulatory mechanisms into the model.ResultsWe benchmark our method against various regression, support vector machines and artificial neural network models and demonstrate the ability of our method in predicting the clinical outcomes using clinical trial data on acute rejection in kidney transplantation and response to Infliximab in ulcerative colitis. We show that integration of prior biological knowledge into the classification as developed in this paper, significantly improves the robustness and generalizability of predictions to independent datasets. We provide a Java code of our algorithm along with a parsed version of the STRING DB database.ConclusionIn summary, we present a method for prediction of clinical phenotypes using baseline genome-wide expression data that makes use of prior biological knowledge on gene-regulatory interactions in order to increase robustness and reproducibility of omic-scale markers. The integrated group-wise regularization methods increases the interpretability of biological signatures and gives stable performance estimates across independent test sets.

Dataset Information

Robust phenotype prediction from gene expression data using differential shrinkage of co-regulated genes.

Publications

Robust phenotype prediction from gene expression data using differential shrinkage of co-regulated genes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets